Published on
January 13, 2026
- 15:15 GMT
Ainnocence and Phase Advance Enter Industry-First AI Collab to Reduce Drug Development Timeline and Clinical Trial Risk
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. SAN FRANCISCO, CA, CA, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- Ainnocence and Phase Advance Announce Industry-First AI Collaboration to Transform Drug Development Timelines and Reduce Clinical Trial Risk Ainnocence, a next-generation AI-driven biotechnology company, and Phase Advance, a pioneering AI company capable of predicting drug …
Distribution channels:
Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry
...
